Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Robinson, Stephen [VerfasserIn]   i
 Dietrich, Sascha [VerfasserIn]   i
 Dreger, Peter [VerfasserIn]   i
Titel:Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma
Titelzusatz:a retrospective study from the EBMT Lymphoma Working Party
Verf.angabe:Stephen P. Robinson, Ariane Boumendil, Herve Finel, Karl S. Peggs, Patrice Chevallier, Jorge Sierra, Jürgen Finke, Xavier Poiré, Natacha Maillard, Noël Milpied, Ibrahim Yakoub-Agha, Mickey Koh, Nicolaus Kröger, Arnon Nagler, Yener Koc, Sascha Dietrich, Silvia Montoto, Peter Dreger
E-Jahr:2018
Jahr:15 January 2018
Umfang:8 S.
Fussnoten:Gesehen am 14.04.2020
Titel Quelle:Enthalten in: Bone marrow transplantation
Ort Quelle:London : Springer Nature, 1997
Jahr Quelle:2018
Band/Heft Quelle:53(2018), 5, Seite 617-624
ISSN Quelle:1476-5365
Abstract:Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. A total of 324 patients, median age 57 years (range 31-70), underwent a RIST between 2000 and 2008; 43% of the patients had received >3 lines of prior therapy, including an autoSCT in 46%. Non-relapse mortality (NRM) was 10% at 100 days and 24% at 1 year and was lower for patients receiving anti-thymocyte globulin (ATG)/ALG (RR 0.59, p = 0.046). After a median follow-up of 72 months (range 3-159), 118 patients relapsed at a median of 8 months post RIST (range 1-117). The cumulative incidence of relapse was 25% and 40% at 1 and 5 years, respectively, and was associated with chemorefractory disease (HR 0.49, p = 0.01) and the use of CAMPATH (HR 2.59, p = 0.0002). The 4-year progression-free survival rate and overall survival rate was 31 and 40%, respectively. RIST results in long-term disease-free survival in about 30% of the patients, including those patients relapsing after a prior autoSCT.
DOI:doi:10.1038/s41409-017-0067-3
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1038/s41409-017-0067-3
 Volltext: https://www.nature.com/articles/s41409-017-0067-3
 DOI: https://doi.org/10.1038/s41409-017-0067-3
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1694461467
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68563893   QR-Code
zum Seitenanfang